

LAW OFFICES OF  
**JACOBSON HOLMAN**  
PROFESSIONAL LIMITED LIABILITY COMPANY  
400 SEVENTH STREET, N. W.  
WASHINGTON, D. C. 20004  
(202) 638-6666

ARVEY B. JACOBSON, JR.  
JOHN CLARKE HOLMAN  
TIMOR L. MOSKOWITZ  
ALEX S. MELSER  
MICHAEL R. SLOBASKY  
MARSHA G. GENTNER  
NATHAN L. SCHERER  
DAVID M. AISENBERG  
GEORGE W. LEWIS  
WILLIAM E. PLAYER  
YOUNG S. HAM  
PHILIP L. O'NEILL  
LINDA J. SHAPIRO  
LEESA N. WEISS  
SUZIN C. BAILEY\*  
MATTHEW J. CUCCIAS  
DANIEL K. DORSEY  
MONICA LEWIS\*  
SUZANNAH K. SUNDBY\*

JACOBSON HOLMAN STERN  
OF COUNSEL  
MARVIN R. STERN  
NATHANIEL A. HUMPHRIES

TELEFAX:  
(202) 393-5350  
(202) 393-5351  
(202) 393-5352

E-MAIL: IP@JPHS.COM  
INTERNET: WWW.JPHS.COM

\*BAR OTHER THAN D

Writer's Direct Dial  
(202) 662-8497  
SSundby@JHIP.com



12 October 2001

Commissioner for Patents  
Washington, D.C. 20231

**Box Patent Application**

Dear Sir:

Re: New U.S. Utility Patent Application  
Serial No.: TO BE ASSIGNED  
For: MICROFLUIDIZED LEISHMANIA LYSATE AND  
METHODS OF MAKING AND USING THEREOF  
Inventors: MAGILL et al.  
Atty Docket No.: P66822US0 (WRAIR 98-40/46)

**I. Enclosures:**

We enclose the following papers for filing in the United States Patent and Trademark Office in connection with the above-identified patent application.

1. U.S. Utility Patent Application entitled:

**MICROFLUIDIZED LEISHMANIA LYSATE AND METHODS OF MAKING AND USING THEREOF**

and naming the following as inventor(s):

- |   |   |  |
|---|---|--|
| 1. Alan J. Magill<br>9917 Hillridge Drive<br>Kensington, MD 20895 | 2. John M. Stiteler<br>8369 Luce Court<br>Springfield, VA 22153 | 3. Max Grogl<br>10345 Buglenote Way<br>Columbia, MD 21044                |
| 4. Edgar D. Rowton<br>9002 50th Place<br>College Park, MD 20740   | 5. Kenneth H. Eckels<br>15317 Emory Lane<br>Rockville, MD 20853 | 6. William R. Ballou<br>12031 Remington Drive<br>Silver Spring, MD 20902 |

- a. A specification containing:
- (i) 19 pages of description;
  - (ii) 4 pages of claims (28 claims);
  - (iii) 1 page of Abstract
- b. 1 sheets of drawings: (1 Figure ).

The filing fee has been calculated as shown below:

	(Col. 1)	(Col. 2)
For	No. Filed	No. Extra
Basic Fee		
Total Claims	28-20 =	8
Indep. Claims	2-3 =	0
Multiple Dependent Claim Presented		

\*If the difference in Col. 1 is less than zero, enter "0"  
in Col. 2

SMALL ENTITY	
Rate	Fee
	\$370.00
x 9 =	
x 42=	
+ 140=	
Total	

or  
or  
or  
or  
or  
or

LARGE ENTITY	
Rate	Fee
	\$740.00
x 18 =	\$144.00
x 84 =	
+ 280 =	
Total	\$884.00

## II. Filing under 37 C.F.R. § 1.53(b)

This application is being filed under the provisions of 37 C.F.R. § 1.53(b). Applicants respectfully await notification from the Patent and Trademark Office of the time set for filing any missing parts.

Also enclosed herewith are the following:

1. ☐ Oath/Declaration.
2. ☐ Power of Attorney.
3. Two (2) return postcards.

## III. Correspondence Address.

The correspondence address for this application is (37 C.F.R. §1.51(vii)):

**Office of the Staff Judge Advocate  
U.S. Army Medical Research and Materiel Command  
ATTN: MCMR-JA (Ms. Elizabeth Arwine)  
504 Scott Street  
Fort Detrick, MD 21702-5012**

**IV. Statement as to whether invention was made by an agency of the U.S. Government or under contract with an agency of the U.S. Government. (37 C.F.R. §1.51(viii)):**

This invention was made by the United States Army Medical Research and Materiel Command, which is an agency of the United States Government.

**V. Small Entity Status Assertion under 35 U.S.C. 1.27(c)(1):**

**APPLICANT IS NOT A SMALL ENTITY.**

**VI. Claim for Priority:**

- ☐ Foreign priority benefits under 35 U.S.C. 119(a)-(d) is hereby claimed of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Foreign Application: Country: Filing Date:

- ☐ The benefit of priority under 35 U.S.C. 119(e) is hereby claimed of the United States provisional patent application(s) referenced above.
- ☐ The benefit of priority under 35 U.S.C. 120 is hereby claimed of any United States non-provisional patent application(s) listed below:

Serial No.: Filing Date: Status:

**VII. Method of fee payment**

- ☐ Check in the amount of \_\_\_\_ is enclosed.
- ☒ Charge Account No. 210-380, Reference No. **P66822US0 (WRAIR 98-40/46)** in the amount of **\$884.00**
- ☒ The U.S. Patent and Trademark Office is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. **210-380** Reference No. **P66822US0 (WRAIR 98-40/46)**. A duplicate copy of this sheet is attached.
- ☒ Any additional filing fees required under 37 C.F.R. §1.16.
- ☒ Any patent application processing fees under 37 C.F.R. §1.17.